摘要
目的探讨0.1%维生素K_1(VitK_1)乳剂对结直肠癌患者应用西妥昔单抗所致皮肤毒性反应的影响。方法将住院应用西妥昔单抗治疗的结直肠癌患者60例按人院顺序编号分为试验组(A病房)和对照组(B病房),每组30例。对照组予常规护理,试验组在常规护理的基础上于应用西妥昔单抗当日起予0.1%VitK_1乳剂每日三次涂于面、颈、胸、背、指(趾)甲缘。结果应用西妥昔单抗8周后试验组患者的皮肤瘙痒、皮肤干燥较对照组有明显改善,差异具有统计学意义(W=708.000,P=0.001;W=662.500,P=0.000)。结论 0.1%VitK_1乳剂有助于改善结直肠癌患者应用西妥昔单抗治疗所致皮肤毒性反应中的皮肤瘙痒和皮肤干燥症状。
Objective To explore the effect of 0. 1% VitK1 on the colorectal cancer patients with skin toxicity under eetuximab treatment. Method 60 inpatients with eolorectal cancer treated by cetuximab were divided into experimental group （ward A） and control group （ward B）, with 30 cases in each Patients in the control group received only routine care, and the experimental group had had 0. 1% VitK1 applied on the face, neck, chest, back, and finger （toe） nail mar- gin three times a day as well as routine care. Result After 8 weeks of cetuximab treatment, the skin itching and xerosis cutis symptoms of patients in experimental group were significantly improved compared with those in control group （ W = 708. 000, P =0. 001 ; W=662. 500, P =0. 000）. Conclusion The application of 0. 1% VitK1 can improve the skin itch- ing and xerosis cutis caused by cetuximb in eolorectal cancer patients.
出处
《癌症进展》
2013年第6期587-591,595,共6页
Oncology Progress
